1234015-54-3

Basic information

• Product Name: 5-(5-(2-(3-aMinopropoxy)-6-Methoxyphenyl)-1H-pyrazol-3-ylaMino)pyrazine-2-carbonitrile hydrochloride
• Synonyms: 5-(5-(2-(3-aMinopropoxy)-6-Methoxyphenyl)-1H-pyrazol-3-ylaMino)pyrazine-2-carbonitrile hydrochloride;5-(5-(2-(3-aMinopropoxy)-6-Methoxyphenyl)-1H-pyrazol-3-ylaMino)pyrazine-2-carbonitrile dihydrochloride;LY2606368 dihydrochloride;LY-2606368 dihydrochloride;Prexasertib (LY2606368) 2HCl;Prexasertib HCl (LY2606368)
• CAS NO: 1234015-54-3
• Molecular Formula: C18H21Cl2N7O2
• Molecular Weight: 438.31104
• Mol File: 1234015-54-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 5-(5-(2-(3-aMinopropoxy)-6-Methoxyphenyl)-1H-pyrazol-3-ylaMino)pyrazine-2-carbonitrile hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(5-(2-(3-aMinopropoxy)-6-Methoxyphenyl)-1H-pyrazol-3-ylaMino)pyrazine-2-carbonitrile hydrochloride(1234015-54-3)
• EPA Substance Registry System: 5-(5-(2-(3-aMinopropoxy)-6-Methoxyphenyl)-1H-pyrazol-3-ylaMino)pyrazine-2-carbonitrile hydrochloride(1234015-54-3)

Safety Data

• Hazardous Substances Data: 1234015-54-3(Hazardous Substances Data)

Usage

Description

Prexasertib dihydrochloride is a small molecule inhibitor of checkpoint kinase 1 (CHK1), a key enzyme involved in the regulation of the cell cycle and DNA damage response. It is being developed for the treatment of cancer, as it disrupts DNA repair and cell cycle progression, leading to the induction of cell death in cancer cells. This targeted approach has the potential to be an effective treatment for various types of cancer, and prexasertib dihydrochloride is currently under investigation in clinical trials for its therapeutic potential.

Uses

Used in Oncology:
Prexasertib dihydrochloride is used as an anticancer agent for its ability to inhibit the CHK1 enzyme, which is crucial in the regulation of the cell cycle and DNA damage response in cancer cells. By disrupting DNA repair and cell cycle progression, prexasertib dihydrochloride induces cell death, making it a promising candidate for the treatment of various types of cancer.
Used in Clinical Trials:
Prexasertib dihydrochloride is used as a subject of investigation in clinical trials to evaluate its therapeutic potential and effectiveness in treating cancer. These trials aim to determine the safety, tolerability, and optimal dosing of the compound, as well as its potential synergistic effects when combined with other cancer treatments.